ADIPOQ and alcoholic liver diseases: Combined, these data indicate that activating adiponectin and adiponectin mediated signaling pathways may not be a successful strategy for the prevention/treatment of alcoholic liver disease, as its levels are already increased with, at least in some models of, chronic ethanol exposure.